Exicure (NASDAQ:XCUR) Posts Quarterly Earnings Results, Beats Expectations By $18.42 EPS

Exicure (NASDAQ:XCUR) released its quarterly earnings data on Friday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.42, FiscalAI reports.

Exicure Price Performance

Shares of XCUR stock traded down $0.05 during trading hours on Friday, hitting $1.26. The company had a trading volume of 15,593 shares, compared to its average volume of 178,948. The stock has a market capitalization of $8.03 million, a PE ratio of -0.81 and a beta of 3.65. The company’s fifty day moving average is $1.99 and its 200 day moving average is $3.16. Exicure has a fifty-two week low of $1.18 and a fifty-two week high of $9.48.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Exicure presently has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.